Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Novavax (Nasdaq: NVAX) announced its participation in a fireside chat at the H.C. Wainwright Virtual Global Life Sciences conference on March 9, 2021. The discussion will focus on Novavax's COVID-19 vaccine candidate, NVX-CoV2373, featuring Dr. Gregory M. Glenn and John Trizzino as speakers. The session will be available on-demand starting at 7:00 a.m. ET. A replay will also be accessible for 90 days on the company’s website.
Novavax specializes in creating next-generation vaccines to combat serious infectious diseases.
Details
News Market Reaction – NVAX
The recorded move for NVAX in the trading session of this news was +7.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion.
| Fireside Chat details: | |
| Date: | Tuesday, March 9, 2021 |
| Time: | Available on-demand starting at 7:00 a.m. Eastern Time (ET) |
| Participants: | Gregory M. Glenn, M.D., President, Research and Development and John Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer |
A replay of the recorded fireside session will be available through the events page of the Company’s website at ir.novavax.com for 90 days.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Jennifer Porcelli | 617-974-8659
jporcelli@soleburytrout.com
Media
Amy Speak | 617-420-2461
Laura Keenan | 410-419-5755
media@novavax.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.